HRTX

Capital One Initiates Coverage of Heron Therapeutics (HRTX) with Overweight Recommendation

Fintel reports that on April 23, 2024, Capital One initiated coverage of Heron Therapeutics (NasdaqCM:HRTX) with a Overweight recommendation.

Analyst Price Forecast Suggests 175.68% Upside

As of April 17, 2024, the average one-year price target for Heron Therapeutics is 7.14. The forecasts range from a low of 5.05 to a high of $9.45. The average price target represents an increase of 175.68% from its latest reported closing price of 2.59.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Heron Therapeutics is 220MM, an increase of 73.46%. The projected annual non-GAAP EPS is -0.33.

What is the Fund Sentiment?

There are 275 funds or institutions reporting positions in Heron Therapeutics. This is a decrease of 8 owner(s) or 2.83% in the last quarter. Average portfolio weight of all funds dedicated to HRTX is -1.67%, a decrease of 2,018.81%. Total shares owned by institutions decreased in the last three months by 10.43% to 118,343K shares. HRTX / Heron Therapeutics, Inc. Put/Call Ratios The put/call ratio of HRTX is 0.09, indicating a bullish outlook.

What are Other Shareholders Doing?

HRTX / Heron Therapeutics, Inc. Shares Held by Institutions

Rubric Capital Management holds 26,714K shares representing 17.77% ownership of the company. No change in the last quarter.

Velan Capital Investment Management holds 6,987K shares representing 4.65% ownership of the company. No change in the last quarter.

Franklin Resources holds 6,405K shares representing 4.26% ownership of the company. In it's prior filing, the firm reported owning 6,958K shares, representing a decrease of 8.64%. The firm increased its portfolio allocation in HRTX by 39.79% over the last quarter.

Clearline Capital holds 6,069K shares representing 4.04% ownership of the company. In it's prior filing, the firm reported owning 6,150K shares, representing a decrease of 1.34%. The firm increased its portfolio allocation in HRTX by 16.22% over the last quarter.

Orbimed Advisors holds 5,929K shares representing 3.94% ownership of the company. In it's prior filing, the firm reported owning 803K shares, representing an increase of 86.46%. The firm increased its portfolio allocation in HRTX by 1,046.06% over the last quarter.

Heron Therapeutics Background Information
(This description is provided by the company.)

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from pain or cancer.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.